Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 5/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18199879 | 0.83 | KIF11 (0.33) | KIF11ERN1MEN1LMNATHRB | |
| SCHEMBL9340566 | 0.82 | KIF11 (0.42) | KIF11ERN1CTSSPIM1PIM3 | |
| SCHEMBL622545 | 0.81 | ERN1 (0.44) | KIF11ERN1CTSSPIM1PIM3 | |
| SCHEMBL31306390 | 0.81 | TDP1 (0.47) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL31306389 | 0.81 | TDP1 (0.47) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL1806887 | 0.81 | TDP1 (0.47) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL21384829 | 0.78 | PDE2A (0.35) | KIF11PDE2AAPP | |
| SCHEMBL3250664 | 0.74 | ERN1 (0.38) | KIF11ERN1PIM1PIM3MEN1 | |
| SCHEMBL1167283 | 0.74 | MIF (0.47) | NFKB1 | |
| SCHEMBL1167281 | 0.74 | MIF (0.47) | NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20040171637-A1 | Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2004-08-19 | — | — | US | disclosed |
| WO-2004031195-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-04-15 | — | — | WO | disclosed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002072544-A2 | MULTIFLUORO-SUBSTITUTED CHALCONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0396987-B1 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| US-5041683-A | Nuclear-fluorinated trifluoromethylbenzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0396987-A2 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | KIF11 3135/4885PDE2A 3730/4885ERN1 3348/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | KIF11 2448/4885PDE2A 4404/4885ERN1 1853/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | KIF11 1692/4885PDE2A 1287/4885ERN1 3841/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | KIF11 3135/4885PDE2A 3730/4885ERN1 3348/4885 |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | QTRT1, QTRT2, NQO2 | KIF11 3921/4885PDE2A 3701/4885ERN1 1952/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | KIF11 1692/4885PDE2A 1287/4885ERN1 3841/4885 |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | KIF11 2990/4885PDE2A 895/4885ERN1 1472/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | KIF11 2448/4885PDE2A 4404/4885ERN1 1853/4885 |
| US-20040171637-A1 | Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP10, CASP6, CASP1 | KIF11 3378/4885PDE2A 4650/4885ERN1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.